ARS Pharmaceuticals, Inc. (SPRY) Selling, General & Administrative Expenses

Annual SG&A:

$0.00-$47.28M(-100.00%)
December 31, 2024

Summary

  • As of today, SPRY annual SG&A is $0.00, with the most recent change of -$47.28 million (-100.00%) on December 31, 2024.
  • During the last 3 years, SPRY annual SG&A has fallen by -$4.69 million (-100.00%).
  • SPRY annual SG&A is now -100.00% below its all-time high of $47.28 million, reached on December 31, 2023.

Performance

SPRY SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYincome statement metrics

Quarterly SG&A:

$0.00-$54.31M(-100.00%)
September 30, 2025

Summary

  • As of today, SPRY quarterly SG&A is $0.00, with the most recent change of -$54.31 million (-100.00%) on September 30, 2025.
  • Over the past year, SPRY quarterly SG&A has dropped by -$19.28 million (-100.00%).
  • SPRY quarterly SG&A is now -100.00% below its all-time high of $54.31 million, reached on June 30, 2025.

Performance

SPRY Quarterly SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYincome statement metrics

TTM SG&A:

-$735.96M-$80.04M(-12.20%)
September 30, 2025

Summary

  • As of today, SPRY TTM SG&A is -$735.96 million, with the most recent change of -$80.04 million (-12.20%) on September 30, 2025.
  • Over the past year, SPRY TTM SG&A has dropped by -$778.96 million (-1811.33%).
  • SPRY TTM SG&A is now -1053.77% below its all-time high of -$63.79 million.

Performance

SPRY TTM SG&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSPRYincome statement metrics

Selling, General & Administrative Expenses Formula

SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development

SPRY Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-100.0%-100.0%-1811.3%
3Y3 Years-100.0%-100.0%-4891.7%
5Y5 Years-100.0%-100.0%-10000.0%

SPRY Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-100.0%at low-100.0%at low-126.2%+15.9%
5Y5-Year-100.0%at low-100.0%at low-660.8%+15.9%
All-TimeAll-Time-100.0%at low-100.0%at low-1053.8%+15.9%

SPRY Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sep 2025
-
$0.00(-100.0%)
$130.91M(-12.8%)
Jun 2025
-
$54.31M(+32.1%)
$150.19M(+43.3%)
Mar 2025
-
$41.10M(+15.8%)
$104.82M(+46.2%)
Dec 2024
$0.00(-100.0%)
$35.49M(+84.1%)
$71.67M(+66.7%)
Sep 2024
-
$19.28M(+115.6%)
$43.01M(+11.1%)
Jun 2024
-
$8.94M(+12.4%)
$38.70M(-10.1%)
Mar 2024
-
$7.96M(+16.7%)
$43.06M(-8.9%)
Dec 2023
$47.28M(+156.2%)
$6.82M(-54.4%)
$47.28M(+16.9%)
Sep 2023
-
$14.98M(+12.6%)
$40.46M(+42.4%)
Jun 2023
-
$13.30M(+9.2%)
$28.41M(+61.8%)
Mar 2023
-
$12.18M(+316.3%)
$17.57M(+14.4%)
Dec 2022
$18.46M
-
-
DateAnnualQuarterlyTTM
Sep 2022
-
$2.93M(+19.0%)
$15.36M(-21.1%)
Jun 2022
-
$2.46M(+5.1%)
$19.47M(-18.1%)
Mar 2022
-
$2.34M(-69.4%)
$23.78M(-15.3%)
Dec 2021
$4.69M(-43.8%)
-
-
Dec 2021
-
$7.64M(+8.5%)
$28.08M(+13.6%)
Sep 2021
-
$7.04M(+4.1%)
$24.71M(+39.8%)
Jun 2021
-
$6.76M(+1.7%)
$17.67M(+44.3%)
Mar 2021
-
$6.65M(+55.9%)
$12.25M(+90.5%)
Dec 2020
$8.34M(+225.6%)
$4.26M(+218.9%)
$6.43M(+127.7%)
Jun 2020
-
$1.34M(+61.5%)
$2.82M(+90.0%)
Mar 2020
-
$828.00K(+25.8%)
$1.49M(+125.8%)
Dec 2019
$2.56M(-27.1%)
$658.00K
$658.00K
Dec 2018
$3.52M
-
-

FAQ

  • What is ARS Pharmaceuticals, Inc. annual SG&A?
  • What is the all-time high annual SG&A for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. annual SG&A year-on-year change?
  • What is ARS Pharmaceuticals, Inc. quarterly SG&A?
  • What is the all-time high quarterly SG&A for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. quarterly SG&A year-on-year change?
  • What is ARS Pharmaceuticals, Inc. TTM SG&A?
  • What is the all-time high TTM SG&A for ARS Pharmaceuticals, Inc.?
  • What is ARS Pharmaceuticals, Inc. TTM SG&A year-on-year change?

What is ARS Pharmaceuticals, Inc. annual SG&A?

The current annual SG&A of SPRY is $0.00

What is the all-time high annual SG&A for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high annual SG&A is $47.28M

What is ARS Pharmaceuticals, Inc. annual SG&A year-on-year change?

Over the past year, SPRY annual SG&A has changed by -$47.28M (-100.00%)

What is ARS Pharmaceuticals, Inc. quarterly SG&A?

The current quarterly SG&A of SPRY is $0.00

What is the all-time high quarterly SG&A for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high quarterly SG&A is $54.31M

What is ARS Pharmaceuticals, Inc. quarterly SG&A year-on-year change?

Over the past year, SPRY quarterly SG&A has changed by -$19.28M (-100.00%)

What is ARS Pharmaceuticals, Inc. TTM SG&A?

The current TTM SG&A of SPRY is -$735.96M

What is the all-time high TTM SG&A for ARS Pharmaceuticals, Inc.?

ARS Pharmaceuticals, Inc. all-time high TTM SG&A is -$63.79M

What is ARS Pharmaceuticals, Inc. TTM SG&A year-on-year change?

Over the past year, SPRY TTM SG&A has changed by -$778.96M (-1811.33%)
On this page